Aprepitant-based triple regimen
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Aprepitant-based triple regimen, covering 2015-07-30 to 2015-07-30. Get the full timeline:
Most recent: Clinical Trial Update: A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) [Phase 4]